L3VLUP
ProSign in

ARQT · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ARQTVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ARQT
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterARQTVRTX
Q3 2020none listed holders, n.a.31 holders, $21.9bn
Q4 20201 holders, $25m30 holders, $18.4bn
Q1 20211 holders, $13m31 holders, $15.4bn
Q2 20211 holders, $24m30 holders, $12.7bn
Q3 20211 holders, $48m35 holders, $10.1bn
Q4 20212 holders, $57m28 holders, $12.4bn
Q1 20222 holders, $34m23 holders, $16.1bn
Q2 20221 holders, $42m25 holders, $18.1bn
Q3 20223 holders, $86m22 holders, $18.4bn
Q4 20224 holders, $44m28 holders, $18.4bn
Q1 20234 holders, $57m26 holders, $21.4bn
Q2 20234 holders, $45m27 holders, $24.7bn
Q3 20233 holders, $13m33 holders, $24.3bn
Q4 2023none listed holders, n.a.32 holders, $28.6bn
Q1 20244 holders, $23m31 holders, $29.8bn
Q2 20245 holders, $15m29 holders, $33.4bn
Q3 20243 holders, $3.4m27 holders, $33.5bn
Q4 20244 holders, $30m26 holders, $28.5bn
Q1 20253 holders, $12m21 holders, $35.4bn
Q2 20255 holders, $63m21 holders, $32.3bn
Q3 20254 holders, $64m22 holders, $25.9bn
Q4 20254 holders, $85m26 holders, $31.8bn
Q1 20265 holders, $118m25 holders, $31.8bn
Q2 20263 holders, $112m26 holders, $34.6bn
ARQT

Arcutis Biotherapeutics Inc

Holders
3
Reported value
$3.4m
Buyers
0
Sellers
0

Breadth 0 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
27
Reported value
$33.5bn
Buyers
17
Sellers
10

Breadth +7 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2024

Among the 30 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only ARQT (3)

Farallon Capital Management LLC, Moore Capital Management LP, PDT Partners LLC

Only VRTX (27)

AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Artisan Partners LP, Baillie Gifford & Co, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, D. E. Shaw & Co., Egerton Capital UK LLP, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Neuberger Berman Group LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Two Sigma Investments LP, Voloridge Investment Management LLC, Wellington Management Group LLP, and 2 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →